在74%的试验参与者中,三联阴性乳腺癌实验疫苗表现出安全性并引发免疫反应。 An experimental vaccine for triple-negative breast cancer showed safety and triggered immune responses in 74% of trial participants.

由克利夫兰诊所和Anixa生物科学公司开发的三排阴性乳腺癌实验疫苗第一阶段临床试验显示,该疫苗是安全的,在35名参与者中,包括高危个人和残余疾病患者在内的74%的参与者中,引发了可计量的免疫反应。 A Phase 1 clinical trial of an experimental vaccine for triple-negative breast cancer, developed by Cleveland Clinic and Anixa Biosciences, showed the vaccine is safe and triggered a measurable immune response in 74% of 35 participants, including high-risk individuals and those with residual disease. 瞄准大多数TNBC肿瘤中存在的蛋白α-肾上腺素,但哺乳后健康乳房组织中没有这种蛋白质,疫苗激活T细胞,可能有助于防止癌症复发。 Targeting the protein α-lactalbumin, which is present in most TNBC tumors but not in healthy breast tissue after lactation, the vaccine activated T cells and may help prevent cancer recurrence. 这些结果在2025年圣安东尼奥乳腺癌专题讨论会上提出,并在《自然医学》上发表,标志着朝向一项预防战略迈出了重大一步,这一战略针对治疗疗法有限的难以治疗的癌症。 The results, presented at the 2025 San Antonio Breast Cancer Symposium and published in Nature Medicine, mark a significant step toward a preventive strategy for a hard-to-treat cancer with limited therapies. 研究人员计划在2026年底进行第二阶段试验,以评估有效性。 Researchers plan a Phase 2 trial in late 2026 to assess effectiveness.